Treatment Studies

Research studies help us to advance our knowledge of ADHD and other behavioral disorders. Participating in clinical trials is a great way to access new and cutting-edge treatment

Please contact us at (310) 267-4798 or adhdandmood@ucla.edu if you are interested or know someone who may be interested in participating. More information about our current and past treatment studies can be found below.

All treatment is provided at no cost. 

Treatment Study for Children and Adolescents with Irritability and Restlessness

STATUS

ACTIVE AND SEEKING PARTICIPANTS

AGE

7 - 17 years of age

ELIGIBILITY
  • Is frequently moody, irritable, cranky, agitated, or distractible

  • Participants must not be diagnosed with autism or Asperger’s disorder.

STUDY LENGTH

12 visits over 3 months

STUDY DETAILS
  • Participants will receive a comprehensive evaluation and be given an ADHD medication and antidepressant (Fluoxetine) or a placebo

  • The study also includes psychological and laboratory testing, interviews, and weekly questionnaires 

FLYER

For more information, please view our study flyer here.

PRINCIPAL INVESTIGATOR: Dr. James McGough

 

Innovative Non-Medication Treatment Study for ADHD

STATUS

ACTIVE AND SEEKING PARTICIPANTS

AGE

8 - 12 years of age

ELIGIBILITY

Diagnosed with ADHD or has symptoms of inattention, hyperacticity, or impulsivity

STUDY LENGTH

8 - 12 weeks

STUDY DETAILS
  • Participants will receive a comprehensive ADHD evaluation, EEGs, weekly questionnaires, and a novel medical treatment

  • For this innovative treatment, mild electrical signals are used to stimulate the brain during sleep in order to improve behaviors associated with ADHD

FLYER

For more information, please view our study flyer here.

PUBLICATIONS

The details and results of our first TNS research study can be found here:
An Eight-week, Open-trial, Pilot Feasibility Study of Trigeminal Nerve Stimulation in Youth With Attention-deficit/Hyperactivity Disorder

PRINCIPAL INVESTIGATOR: Dr. James McGough

 

Treatment for Adolescents with Attention-Deficit/Hyperactivity Disorder

STATUS

IN ANALYSIS - NOT SEEKING PARTICIPANTS

AGE

12 - 17 years of age

ELIGIBILITY

Diagnosed with ADHD or has symptoms of inattention, hyperactivity, or impulsivity

STUDY LENGTH

Weekly visits for up to 7 weeks

STUDY DETAILS
  • Participants will receive a comprehensive evaluation and be given an ADHD medication (methylphenidate) or placebo
  • This study also includes psychological measures and laboratory testing, and weekly questionnaires and interviews

PRINCIPAL INVESTIGATOR: Dr. James McGough

 

Translational Research to Enhance Cognitive Control (TRECC)

STATUS

COMPLETE - NOT SEEKING PARTICIPANTS

STUDY DETAILS

The purpose of TRECC was to compare the effectiveness of Guanfacine, Focalin XR, and combination treatment with the two on ADHD symptoms. Through the study, a better understanding of the relations between genetic, physiological and psychological processes in children with ADHD was gained.  

Thus far, TRECC investigators have published electroencephalogram (EEG) findings from TRECC that focus on how differences in the brain contribute to differences among children diagnosed with ADHD. Read more below! 

PUBLICATIONS

Characterization of the Theta to Beta Ratio in ADHD: Identifying Potential Sources of Heterogeneity

PRINCIPAL INVESTIGATOR: Dr. James McGough

 

Preschoolers with ADHD Treatment Studies (PATS)

STATUS

COMPLETE - NOT SEEKING PARTICIPANTS

STUDY DETAILS

The PATS study aimed to measure the safety and efficacy of immediate-release methylphenidate (MPH-IR) in pre-school children (ages 3-5.5 yrs) diagnosed with ADHD. This study determined that MPH-IR is a safe and effective treatment that can be used to improve ADHD symptoms in pre-school children diagnosed with ADHD. In addition, preschoolers with ADHD continue to benefit from treatment with a stimulant medication. Find out more about the study details and results in the articles below.

PUBLICATIONS

Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS)

Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD

Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS)

PRINCIPAL INVESTIGATOR: Dr. James McGough

 

ADHD Genetics

STATUS

COMPLETE - NOT SEEKING PARTICIPANTS

STUDY DETAILS

The ADHD genetics study demonstrated that specific variations in one location on the genome (specifically DRD4 and chromosome 16p13) may contribute to the risk for ADHD, specifically ADHD inattentive type. 

PUBLICATIONS

Evidence for linkage of a tandem duplication polymorphism up- stream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD)

Genetic Linkage of Attention-Deficit/Hyperactivity Disorder on Chromosome 16p13, in a Region Implicated in Autism

PRINCIPAL INVESTIGATOR: Dr. James McGough